Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies

Andrew Clamp ¹, Sarah Danson , Mark Clemons

⁰Department of Medical Oncology, Christie Hospital, Manchester, UK.

The Lancet. Oncology +

|

October 10, 2002

View abstract on PubMed

Summary

This review compares breast cancer risk models, Gail and Claus, highlighting how incorporating estrogen exposure improves risk prediction for chemoprevention strategies like tamoxifen.

Area Of Science

Oncology
Epidemiology
Preventive Medicine

Background

Breast cancer is a significant global health concern for women.
Hormonal and genetic factors influence breast cancer risk.
Mathematical models aid in estimating individual breast cancer risk.

Purpose Of The Study

To review and compare the Gail and Claus breast cancer risk models.
To explore methods for enhancing breast cancer risk prediction.
To evaluate breast cancer chemoprevention trials and future interventions.

Main Methods

Comparative analysis of the Gail and Claus risk assessment models.
Investigation of estrogen exposure markers for improved risk stratification.
Appraisal of clinical trials for breast cancer chemoprevention.

Main Results

The Claus model primarily uses family history, while the Gail model incorporates estrogen exposure markers.
More sophisticated measures of estrogen exposure can enhance model discriminatory power.
Tamoxifen is licensed in the USA for breast cancer chemoprevention based on trial data.

Conclusions

Risk assessment models are crucial for identifying women who may benefit from chemoprevention.
Improving risk prediction accuracy is key to effective breast cancer prevention strategies.
Further research into novel agents and interventions is needed to enhance breast cancer risk reduction.

Related Concept Videos